DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s OA forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of OA?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OA over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology forecasts one OA patient population:
Diagnosed Lifetime Prevalence of Osteoarthritis per 1,000 People of All Ages in 2021 and 2031ttttttttttttttttt
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Lifetime Prevalent Cases of Osteoarthritis over the Next 10 Yearstttttttttttttttttttttttttt
Number of Additional Diagnosed Lifetime Prevalent Cases of Osteoarthritis in 2031 in the Countries Under Study due to Trends in Risk tttttttttttttt
Epidemiology Data
Methods
Diagnosed Prevalent Cases of Osteoarthritis
Reference Materials
Literature Review
Studies Included in the Analysis of Osteoarthritis
Studies Excluded from the Analysis of Osteoarthritis
Risk/Protective Factors
Risk/Protective Factors for Osteoarthritis
Bibliography
Abbreviations
Glossary
Aishwarya S. Ambat
Aishwarya S. Ambat, M.P.H., is an associate epidemiologist at Clarivate. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy.
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
